Actively Recruiting
Real-World Outcomes and Clinical Features of Chinese Patients With Hypertrophic Cardiomyopathy in a Prospective Cohort Study
Led by Second Affiliated Hospital, Zhejiang University, School of Medicine · Updated on 2026-09-15
3000
Participants Needed
2
Research Sites
73 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a prospective cohort study to explore the baseline characteristics and treatment patterns of Chinese patients diagnosed with hypertrophic cardiomyopathy HCM based on the 2023 guidelines. The study aims to observe real-world treatment approaches and long-term outcomes in this population, providing insights into the management and prognosis of HCM in clinical practice. Participants with HCM receive various treatments including medication, interventional procedures, or surgery according to real-world clinical strategies. No specific interventions are applied as part of the study itself. Patients are consecutively enrolled and followed over time to monitor their health and treatment outcomes. During the study, researchers will track important health events such as cardiovascular complications over a 5-year period. Assessments include monitoring mortality, arrhythmias, heart failure hospitalizations, and quality of life using tools like the New York Heart Association Classification and Kansas City Cardiomyopathy Questionnaire-23. Blood markers such as BNPNT-proBNP and Troponin TI will also be measured. The study duration extends until 2032, offering long-term follow-up data on patient prognosis.
CONDITIONS
Brief Title
A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population
Research Team
J
Jianqiang Song, MD
S
Shitian Guo, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here